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Herpes simplex virus 1 targets
IRF7 via ICP0 to limit type I IFN
induction
David Shahnazaryan1,2, Rana Khalil3, Claire Wynne4, Caroline A. Jefferies5,6,
Joan Ní Gabhann‑Dromgoole1,3,6* & Conor C. Murphy1,2,6
Herpes simplex keratitis (HSK), caused by herpes simplex virus type 1 (HSV-1) infection, is the
commonest cause of infectious blindness in the developed world. Following infection the virus is
initially suspended in the tear film, where it encounters a multi-pronged immune response comprising
enzymes, complement, immunoglobulins and crucially, a range of anti-viral and pro-inflammatory
cytokines. However, given that HSV-1 can overcome innate immune responses to establish lifelong
latency throughout a susceptible individual’s lifetime, there is significant interest in understanding
the mechanisms employed by HSV-1 to downregulate the anti-viral type I interferon (IFN) mediated
immune responses. This study aimed to investigate the interactions between infected cell protein
(ICP)0 and key elements of the IFN pathway to identify possible novel targets that contribute to
viral immune evasion. Reporter gene assays demonstrated the ability of ICP0 to inhibit type I IFN
activity downstream of pathogen recognition receptors (PRRs) which are known to be involved in host
antiviral defences. Further experiments identified interferon regulatory factor (IRF)7, a driver of type
I IFN, as a potential target for ICP0. These findings increase our understanding of the pathogenesis of
HSK and suggest IRF7 as a potential therapeutic target.
Herpes simplex keratitis (HSK) is the commonest cause of infectious corneal blindness in the western world1.
There are over 500,000 affected individuals in the United States (US) alone2. The infection is caused by human
herpes simplex virus (HSV)-1 in the majority of cases, with the exception of neonatal herpetic keratitis, where
75% of cases is caused by HSV-23. It is characterised by recurrent episodes of infection and inflammation in
the cornea, which can result in significant corneal scarring and vision loss4,5. Although a significant amount of
research has resulted in a better understanding of the molecular biology and pathogenesis of HSV-1, the herpetic
eye infection remains a serious public health problem due to its significant impact on vision-related and general
health-related quality of life.
Production of type I interferon (IFN-I) downstream of viral detection is a key component of the innate
immune antiviral response6. In addition to Toll-like receptor (TLRs), retinol-inducible gene-I (RIG-I)-like
receptor (RLR) and nucleotide-binding oligomerization domain (NOD)-like receptor (NLRs), cytosolic DNA
sensors are also involved in the recognition of HSV-1. During HSV-1 infection, pattern recognition receptors
(PRRs) including TLRs, RLRs and NLRs, recognise structurally conserved pathogen-associated molecular patterns (PAMPs) and trigger the production of type I interferon (IFN-I) and other pro-inflammatory c ytokines6.
TLR-mediated signalling through the downstream adapters Toll/IL-1R domain-containing adaptor-inducing
IFN-β (TRIF) and myeloid differentiation factor 88 (MyD88) leads to activation of interferon regulatory factors
(IRFs) and nuclear factor-kappa B (NFκB). RIG-I and melanoma differentiation-associated protein 5 (MDA5)
detect distinct viral RNA structures and signal through the adaptor protein mitochondrial antiviral signaling protein (MAVS, or IPS-1/VISA/Cardif) resulting in IRF3 and NF-κB activation. RIG-I is an intracellular
receptor for double-stranded RNA (dsRNA) viruses and as HSV-1 is a DNA virus, would not be expected to
recognise double-stranded DNA (dsDNA) of HSV-1. However, it is known that HSV-1 synthesises dsRNA as a
by-product of viral replication enabling its detection by RIG-17. Additionally HSV-1 replicates more robustly
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in human hepatoma cells line lacking a functional RIG-I, suggesting a link between HSV-1 and RIG-I8,9. More
recently several cytosolic DNA sensors have also been identified, including DNA-dependent activator of IFN
regulatory factors (DAI), interferon gamma inducible protein 16 (IFI16), RNA polymerase III (Pol III), DEAD
box helicase 41 (DDX41), and cyclic GMP-AMP synthase (cGAS), that contribute to initiation of host immune
response upon detection of viral nucleic a cids10. cGAS, IFI16 and DDX41 signal through a common adaptor
molecule known as Stimulator of IFN genes (STING). STING functions to recruit and activate TANK-binding
kinase 1 (TBK) culminating in the activation of IRF3 and the induction of type I IFNs.
During evolution many viruses have developed mechanisms to evade host responses and specifically the
production of IFN-I by targeting different components downstream of the PRRs and cytosolic nucleic acid
receptors11. IFN-I is essential to limit HSV-1 replication in the cornea as well as being required to limit the
systemic spread of infection12, and HSV-1 has evolved multiple strategies to evade the host immune response
in order to establish latency13,14. The HSV-1 encoded protein, infected cell protein 0 (ICP0), has been studied
extensively in this regard, as it has been implicated in the pathogenesis of HSV-1 infection. ICP0 is a nuclear
phosphoprotein that plays a crucial role in multiple aspects of the viral life cycle, including transactivation of
HSV-1 gene e xpression15, initiation of lytic i nfection16–18 and establishment o
 f19, and reactivation from, a latent
viral state20–22. Infection of cultured cells with an immediate early (IE) gene-deficient HSV-1 mutant which does
not encode ICP0 is known to lead to complete repression of the viral genome and establishment of a quiescent
state, with the only method of reactivation being to reintroduce ICP0 by s uperinfection23–26.
ICP0, an E3 ubiquitin ligase, has developed various mechanisms to avoid immune-surveillance and promote
viral replication. Studies have revealed that ICP0 induces proteasome-dependent degradation of the promyelocytic leukemia protein (PML) and Sp100 (speckled, 100 kDa) components of nuclear b
 odies27–31. This in turn
drive the dissociation of other host nuclear proteins death domain-associated protein (hDaxx) and ATP-dependent helicase (ATRX) from the viral genome, preventing them from repressing viral gene e xpression32. More
recently, the E3 ligase Really Interesting New Gene (RING) finger domain of ICP0 has been shown to be responsible for proteasome-dependent degradation of several cellular proteins such as Nuclear domain 10 (ND10)33. After
entering the cell, HSV-1 is confronted with early host defence transcriptional repression machinery including
the corepressor of RE1 silencing transcription factor (CoREST) complex34. Interestingly it was found that in the
presence of ICP0, 50% of the histone deacetylases that function in the CoREST complex dissociate, preventing
transcriptional repression and enabling immune evasion35–37. Multiple studies have also shown that ICP0 inhibits
IFN-I production resulting in diminished innate immune responses by inhibiting IRF3 regulated transcription38,39
and by inhibiting tumor necrosis factor alpha-induced NF-κB40, STING41 and IFI1642 activation.
The results from our investigations into understanding of the pathogenesis of HSK demonstrate that ICP0
inhibits type I IFN activity downstream of PRRs and cytosolic nucleic acid receptors which are known to be
involved in host antiviral defences. Additionally, we have identified interferon regulatory factor (IRF)7, an
important driver of IFN-I, as a target for ICP0 suggesting an additional immune evasion strategy for HSV-1.

Results

ICP0 acts downstream of RIG‑I and TBK1 to negatively regulate activation of the IFN‑β pro‑
moter. Production of IFN-I downstream of TLRs and cytosolic nucleic acid receptors is a key component

of the innate immune systems antiviral response. HSV-1 has developed multiple mechanisms of evading host
immune response by targeting different downstream components in order to promote viral replication. Our
initial investigations focussed on identifying IFN-I pathways targeted by ICP0.
To assess how ICP0 affected IFN-β expression we transfected HEK293T cells with increasing concentrations
of ICP0 and assessed its effect on an IFN-β dependent reporter gene (p125-luciferase). In keeping with its role as
a negative regulator of IFN-β induction, ICP0 significantly and dose dependently inhibited RIG-1 driven IFN-β
promoter activity (Fig. 1A). Similar effects of ICP0 on MyD88 and TRIF driven IFN-β promoter activity were
observed (Supplemental Figure 1A,B). Interestingly, ICP0 was also found to inhibit the ability of TBK1 driven
IFN-β responses. As TBK1 is a critical kinase activated by RIG-I and TLR-3/4 in order to phosphorylate IRF3
and IRF7, these results strongly suggested that ICP0 may be acting at the level of TBK1 or potentially targeting
transcription factors downstream (Fig. 1B).
Previous studies have shown that ICP0 has a RING finger domain that functions as an E3 ubiquitin ligase
and is a crucial for many of ICP0’s properties (Fig. 2A). In order to determine whether the E3 ligase activity
of ICP0 was responsible for these effects, we transfected HEK293T cells with increasing amounts of RING
finger deficient ICP0 (ICP0-FXE) and TBK1 to assess its effect on the activation of the pathway. These studies
demonstrated that RING finger-deficient ICP0 loses its suppressive action on IFN-β promoter activity when
driven TBK1 (Fig. 2B), suggesting a role for ubiquitination dependent regulation of this pathway. In contrast,
ICP0-FXE was still able to inhibit TRIF-driven IFN-β promoter activity, suggesting that the effects of ICP0 in
regulating TRIF-driven responses in the cell are independent of any potentially E3 ligase activity ICP0 possesses
(Supplemental Figure 1C). We next assessed a possible interaction between ICP0 and TBK1. FLAG-tagged TBK1
was immunoprecipitated from cells, however no interaction between ICP0 and TBK1 was detected (Fig. 2C).
Given the lack of interaction between TBK1 and ICP0 our results suggested that ICP0 may be targeting IRF3/7
or possibly NFκB downstream of TBK1, which are required for IFN-β expression. In order to determine which
of these transcription factor families may be targeted we utilized reporter gene constructs containing the IRF3/7
(PRDIII-I) or NFκB (PRDII) recognition sites in the IFN-β promoter (Fig. 3A). ICP0 significantly inhibited
TBK-1-driven PRDIII-I-luciferase activity but not PRDII, indicating that the effects of ICP0 were targeting IRF3/
IRF7 activation but not NFκB activity. Interestingly a slight potentiation of the TBK-1 driven PRDII response
was observed (Fig. 3B,C).
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Figure 1.  Full-length ICP0 negatively regulates IFN-β promoter activity in response to multiple drivers. HEK293T cells were transiently transfected with 50 ng of the IFN-β p125 promoter, 5 ng of TK renilla, and increasing
concentrations (10, 50 or 100 ng) of full-length ICP0 as indicated. In addition, cells were cotransfected with
RIG-I (A) or TBK-1 (B) or empty vector (EV) control, as indicated, and assayed for reporter gene activity 18 h
posttransfection. Results are expressed as the mean ± SD in each case are representative of three independent
experiments expressed as fold stimulation over unstimulated empty vector (EV) control. *p < 0.05, **p < 0.01 as
determined by Student t test.

ICP0 regulates the stability of IRF7.

As there is some controversy in the literature regarding the role of
ICP0 in regulating IRF3 activity we next performed stability experiments evaluating IRF3 degradation in the
presence of increasing concentrations of ICP038,43. We determined there was no evidence that IRF3 was being
targeted by ICP0 for degradation (Fig. 4A). Similarly, no effects on the stability of TRAF3 (an adaptor protein
downstream of RIG-I) was observed (Supplemental Figure 2A). In keeping with the role previously ascribed
to ICP0 by Van Lint et al. we observed reduced expression of MyD88 in the presence of ICP0 (Supplemental
Figure 2B)44. Next, we co-transfected HEK293T cells with ICP0 and IRF5 or IRF7. While the stability of IRF5
remained unchanged in the presence of ICP0 (Fig. 4B), there was a significant decrease in IRF7 protein levels
in the presence of ICP0 (Fig. 4C). Furthermore our results show that ICP0 regulates the stability of IRF7 in a
dose dependent manner (Fig. 4D). It is important to note that in each case potential targets were under control
of a constitutive promoter, indicating that any effects of ICP0 on transfected protein levels represent the effect
of ICP0 on protein stability rather than gene expression. Higgs et al. have demonstrated that TRIM21 targets
IRF7 (in addition to IRF3 and IRF5) for degradation after the activation of viral recognition r eceptors45, which is
of interest given that ICP0 is known to interact with other members of the TRIM family such as promyelocytic
leukaemia (PML; also known as TRIM19) to disrupt host antiviral responses. To test whether ICP0 was utilizing
TRIM21 to reduce IRF7 expression we tested their ability to interact in coimmunoprecipitation experiments. No
interaction between ICP0 and TRIM21 was detected (data not shown), suggesting ICP0 is utilizing an unknown
mechanism to regulate IRF7 stability.

Discussion

There has been significant interest in determining the mechanisms used by HSV-1 to regulate IFN-I production given the central role it plays in limiting HSV-1 replication in the cornea as well as the systemic spread of
infection12. This is the first study to demonstrate that ICP0 inhibits the production of IFN-I driven by IRF7.
Furthermore, our co-transfection experiments have shown that expression of IRF7 is decreased by ICP0 in dose
dependent fashion. These findings are another step towards a better understanding of the pathogenesis of HSK
and may potentially identify an additional immune evasion strategy that is utilised by HSV-1.
Numerous HSV-1 viral proteins have been identified that contribute to evasion of the host immune response
through an array of mechanisms including inhibiting NF-κB activation (UL24, UL42, UL36)46–48, modulating
IRF3 (US3, VP16)39,49 or STING (VP22)50 function and consequently IFN-β production. The role of ICP0 is of
particular interest as it has been dubbed as a “promiscuous transactivator” promoting expression of HSV-1 genes
and pathogenesis, in addition to its role in aiding the virus to overcome innate immune responses15–22. Furthermore previous studies have shown that ICP0 diminishes the innate immune response to HSV-1 by inhibiting
IRF3-, NF-κB-, STING- and IFI16-regulated p
 athways38–42. Of note Van Lint et al. have suggested that ICP0
exerts inhibitory effects on TLR2 signaling through the degradation of MyD88 and Mal and other adaptor or
signaling molecules51. Our initial results are in line with their findings whereby we observed decreased expression
of MyD88 by western blot when HEK293T cells were transfected with plasmids encoding MyD88 along with
increasing concentrations of ICP0. In this study we uncovered a novel target for ICP0, the transcription factor
IRF7 in regulating PRR-driven IFN-β expression.
Our initial investigations demonstrated that ICP0 inhibits RIG-I driven IFN-β promoter activity, potentially
indicating that the effects of ICP0 are at a common point on both the TLR and RLR-driven pathways regulating IFN-β production. Studies have shown collaboration of TLRs and cytoplasmic RLRs for triggering antiviral
innate immune r esponses52–54. Both pathways share crucial signalling factors, such as NF-kB, TBK1 and IRF3
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Figure 2.  The RING finger domain of ICP0 is required for it to negatively regulate IFN-β promoter activity
driven by TBK1. (A) A schematic diagram of wildtype ICP0 and its mutant (ICP0 FXE) lacking the RINGfinger domain. Schematic created in Paint Shop Pro, version 5.01, https://www.paintshoppro.com. (B) HEK293T cells were transiently transfected with a reporter construct containing the human IFN-β promoter.
Cells were co-transfected with 50 ng of empty vector (EV) control or TBK1 and increasing amounts (10,
50 or 100 ng) of a plasmid encoding the RING finger domain deficient ICP0 (ICP0-FXE). The amount of
DNA transfected into the cells was normalised using empty vector (EV). Cells were assayed for reporter gene
activity 18 h posttransfection. Results are expressed as the mean ± SD in each case and are representative of
three independent experiments expressed as fold stimulation over unstimulated empty vector (EV) control.
**p < 0.01 as determined by Student t test. (C) 293T cells were transfected with constructs expressing the empty
vector (EV), ICP0, FLAG-tagged TBK1 (lanes 1, 2 and 3) or ICP0 and TBK1 (lanes 4 and 5). Eighteen-hour
posttransfection cell extracts were immunoprecipitated with an anti-FLAG antibody. Anti-IgG antibody was
used in lane 5 for the control. Immunoprecipitated protein complexes were separated by SDS-PAGE and western
blotted using anti-FLAG to detect TBK1 (panel 1) and anti-ICP0 antibody to detect ICP0 (panel 2). Presence
of ICP0 was detected in whole cell lysates (WCL) by immunoblotting (panel 3). α-Actinin served as a loading
control (panel 4). Results are representative of three independent experiments. The full gel image is included in
the supplementary data.

that have already been implicated in the complex interplay between HSV-1 and hosts antiviral r esponses41. As
TBK1 is a key downstream intermediate of these pathways we next investigated the potential that ICP0 could
modulate TBK1 activity55. We observed that ICP0 could disrupt TBK1-mediated IFN responses particularly
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Figure 3.  ICP0 negatively regulates TBK1 driven IFN-β promoter activity within the PRD III-I region. (A) A
diagrammatic representation of the transcription factor binding sites in the IFN-β promoter. (B,C) HEK-293T
cells were transiently transfected with reporter constructs containing PRD III-I-luc (B) or PRD II-luc (D)
that encode the IRF3/IRF7 and NFκB regions of the IFN-β promoter respectively, together with 50 ng TBK-1
or empty vector (EV) control, as indicated, and increasing amounts (10, 50 or 100 ng) of ICP0–expressing
construct. Cells were assayed for reporter gene activity 18 h posttransfection. Results are expressed as the
mean ± SD in each case and are representative of three independent experiments expressed as fold stimulation
over unstimulated empty vector (EV) control. *p < 0.05, **p < 0.01 as determined by Student t test.
within the IRF3/IRF7 binding sites of the IFN-β promoter and consistent with previous studies we have shown
that the E3 ligase activity of ICP0’s RING-finger domain is important for its suppressive action56. Together these
results suggested that ICP0 may be functioning in an analogous manner to HSV-1 viral protein US11, which
inhibits RIG-1 and STING- mediated activation via targeting TBK-157,58. However we did not observe a direct
interaction between ICP0 and TBK1 suggesting that ICP0 could potentially interfere with the activity of TBK1 by
means of translocation rather than direct interaction, similarly to the way ICP0 inhibits IRF3 protein activity59.
Given then effects we observed on the different portions of the IFN-β we next investigated the interferon
regulatory factor (IRF) family of transcription factors for potential interaction partners with ICP0. It has long
been suggested that IRF7, the “master regulator” of IFN-I-dependent immune responses60,61 found in abundance on corneas of patients with a history of HSK, could be targeted by HSV-1 to overcome the innate antiviral
response. The exact molecular mechanisms however were not clear59. An interesting study by Murphy et al.62
found the trigeminal ganglia of double deleted IRF3/7−/− infected mice had significantly higher viral loads than
wild-type or single knockout mice and suggests a synergistic control of HSV-1 pathogenesis by IRF3 and IRF7.
Previous studies have examined the role of ICP0 in regulating IFN-Is via its effect on IRF3 and they report conflicting results. Some studies suggest that there is no direct interaction between ICP0 and I RF338 and that loss of
IRF3 does not affect the replication of HSV-1 in cultured c ells43, while others suggest that ICP0 may instead be
responsible for sequestering IRF3 or machinery required for IRF3 activation and IFN induction42,63,64. Consistent
with Paldino et al.38 we did not observe a direct interaction between IRF3 and ICP0. In co-transfection experiments, we observed that expression of ICP0 culminated in reduced IRF7 expression. This is in keeping with the
importance of IRF7 as a key target for immune evasion strategies as with other herpes viruses including Kaposi’s
sarcoma-associated herpesvirus (KSHV) and Epstein–Barr virus (EBV)65,66.
Although the treatment strategies vary depending on the type of keratitis, none of the current treatments
is able to completely eliminate the virus, and thus the risk of recurrence always exists. Therefore, the optimal
treatment is one that achieves the longest remission with minimal local or systemic side effects. The antiviral
agents acyclovir, ganciclovir and trifluridine are effective against the active virus, but do not eliminate the latent
infection. Long term topical and systemic use is associated with toxicity and adverse e ffects67,68. Similarly, topical steroids, although important therapeutic agents in the management of HSK are associated with risks such as
the development of cataract and g laucoma69–71 as well as facilitation of viral penetration into the c ornea72,73. In
advanced or recurrent cases, long-standing corneal inflammation can result in permanent scarring and loss of
corneal transparency and is the major cause of decreased vision associated with HSK. Once this has occurred,
the only viable treatment becomes corneal transplantation, a procedure that has a dismal long-term visual outcome for this clinical indication with regard to graft survival and an increased risk of recurrence of infection
and therefore v ision74,75.
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◂ Figure 4.  ICP0 induces destabilization of IRF7. (A) 293T cells were transfected with 100ug FLAG-tagged

IRF3 and increasing amounts of ICP0 as indicated (100 ng, 250 ng and 500 ng in lanes 3, 4 and 5 respectively)
or an EV control. Cell lysates were western blotted using anti-FLAG antibody to detect any change in the
expression of IRF3 in the presence of ICP0. Presence of ICP0 was detected by immunoblotting (upper panel).
The β-actin served as a loading control (lower panel). (B,C) 293T cells were transfected with constructs
expressing the empty vector (EV), ICP0 or with key regulators of type 1 interferon pathway (B) Myc-tagged
IRF5 or (C) Flag-tagged IRF7. Eighteen-hour posttransfection cell extracts were western blotted using antiMyc or anti-FLAG antibodies to detect any change in the expression of target proteins. Presence of ICP0 was
detected by immunoblotting (upper panels). β-Actin served as a loading control (lower panels). (D) 293T cells
were transfected with 100 μg FLAG-tagged IRF7 and increasing amounts of ICP0 as indicated (100 ng, 250 ng
and 500 ng in lanes 3, 4 and 5 respectively) or an EV control. Cell lysates were western blotted using antiFLAG antibody to detect any change in the expression of IRF7 in the presence of ICP0. Presence of ICP0 was
detected by immunoblotting (upper panel). The β-actin served as a loading control (lower panel). Results are
representative of three independent experiments. Densitometric analysis was performed and graphs represent
changes in total IRF7 protein levels relative to β-actin (C,D). Results are expressed as the mean ± SD in each
case and are representative of three independent experiments expressed as IRF7 fold expression over β-actin.
*p < 0.05, **p < 0.01 as determined by Student t test.

Therefore more targeted and effective treatments of this potentially blinding condition are necessary. In this
study we have shown that HSV-1 viral protein ICP0 reduces IRF7 protein expression thereby inhibiting IFN-I
responses. IRF7 represents a critical common signalling molecule downstream of RLR, cytosolic nucleic acid
sensor and TLR pathways. There have been several reports in the literature of successful treatment of recalcitrant
herpetic infection in HIV patients with topical 5% Imiquimod, which is a known TLR7 ligand that activates the
TLR7 pathway via I RF776–79. However, none of these studies investigated the use of Imiquimod in ocular herpetic
infection and even though the pathogenesis of the herpetic infections in different parts of the human body is
largely similar, its effectiveness and safety profile for the use in herpetic keratitis remains unanswered. A limited
number of studies reported the use of topical Imiquimod in a variety of other ocular and periocular conditions
such as conjunctival actinic keratosis, periocular actinic keratosis and basal cell carcinoma80 however conjunctivitis and ocular stinging were encountered as adverse effects that resolved on termination of Imiquimod therapy.
As these effects were temporary further research is warranted for its potential role in the eye.
The importance of the adaptor proteins TRIF, RIG-I, TBK1 and MyD88 in the pathogenesis of viral infections has been well e stablished9,41,44,57,81–87. In our study we demonstrated the significant inhibitory effect of the
multifunctional HSV-1 regulatory protein ICP0 on type I IFN responses driven by these proteins which represent
key downstream effector molecules of several TLRs (3, 4 and 7) in addition to RLR and cytosolic nucleic sensing
pathways, consistent with suggestions that HSV-1 targets common components of these pathways to overcome
cross regulation and immune detection52–54. In the search for novel targets for ICP0, we have identified IRF7.
These findings may help pave the way in better understanding the pathogenesis of this blinding condition and
develop more efficient treatment options to reduce the morbidity and improve the quality of lives of the affected
patients.

Materials and methods

Culture of cell lines. As previously described HEK293T cells were cultured in Dulbecco’s Modified Essential Medium (DMEM) high glucose containing stable 2 mM l-glutamine, 10% (v/v) heat inactivated and filtered
sterilised foetal calf serum (FCS) and 100 units/ml Penicillin/100 µg/ml Streptomycin. Cells were maintained
at 37 °C in a humidified atmosphere of 5% CO2. For use in transfection assays, HEK293T cells were typically
seeded at 2.5–3 × 105 cells/ml 24 h prior to transfection88.
Luciferase reporter gene assays. As previously described HEK293T cells (purchased from ATCC, Mid-

dlesex, U.K.) were seeded at a density of 2 × 105/ml (final volume of 200 μl) and were transiently transfected with
combinations of plasmids (indicated in the figure legends), using Metafectene (Biontex, Martinsried, Germany)
according to the manufacturer’s r ecommendations88. We examined the expression of luciferase 18 h after the
initial cell transfection. The supernatant was removed and HEK 293T cells were lysed. The appropriate substrate
was added to the lysed cells (luciferin or coelenterazine) and the luminescence was determined. The amount of
light produced therefore provided a quantitative measure of the effect of ICP0 on expression of the various target
genes. Luciferase activity was normalised to Renilla luciferase plasmid activity to normalise for transfection efficiency. Results are expressed as mean relative stimulation from three separate experiments ± SD.

Plasmids and reagents. Flag-tagged pCMV-IRF3, pEF-Bos-TRIF-Flag, flag-tagged TBK1, and the IFN-β

promoter constructs were from Dr. Kate Fitzgerald (University of Massachusetts Medical School, Worcester,
MA). WT ICP0 and ICP0-FXE were kind gifts from Professor Roger Everett (University of Glasgow, Centre of
Virus Research). Xpress tagged TRIM21 was a gift from Dr. David Rhodes (Cambridge Institute for Medical
Research, Wellcome Trust/MRC Building, Addenbrooke’s Hospital Hills Road, Cambridge CB2 2XY, UK).

Antibodies. Primary antibodies used were anti-TBK1 (Alexis Biochemicals, Lausen, Switzerland), anti-TRIF
(Abnova, Walnut, CA), anti–TNFR-associated factor 3 (TRAF3) (Santa Cruz Biotechnoly), and anti-β-actin
(Abcam, Cambridge, U.K.), anti-IRF3 (Santa Cruz Biotechnologies), anti-Flag (Sigma-Aldrich), anti-Xpress
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(Invitrogen Life), Anti-α-Actinin (H-300) (Santa Cruz Biotechnologies), anti-ICP0 (Santa Cruz Biotechnologies), anti-IRF5 (Cell Signalling), anti-IRF7 (Abcam).

Western blot and immunoprecipitation analysis. Immunoblots were performed as described
 reviously29. Cells were lysed on ice in 1 × radioimmunoprecipitation lysis buffer (1 × PBS, 1% Nonidet P-40,
p
0.5% Na-deoxycholate, 0.1% SDS, 1 mM KF, 1 mM N
 a3VO4, 10 μg/ml leupeptin, and 1 mM PMSF) followed by
immunoprecipitation with anti-TBK1 or anti-TRAF3 precoupled to protein-G Sepharose beads.
For Western blots the molecular weight ladder employed had bands at 170, 130, 100, 70, 55, 40, 35 and
10 kDa. We routinely cut the Western blot membrane just below the 55 kDa band following blotting for IRF7
and TRAF3 and have used this portion to blot for the loading control. As such the image presented in figures
represents the full length gel for loading controls. All Western blot figures were created in Paint Shop Pro, version 5.01, https://www.paintshoppro.com.
Statistical analysis. Data were analysed using Prism 6 software, version 6.07, https://www.graphpad.com/
(GraphPad Software, La Jolla, CA, USA). The Students paired t test was performed to examine changes in luciferase promoter activity. Data was deemed significantly different at P values less than 0.05.

Received: 5 June 2020; Accepted: 10 November 2020

References

1. Dawson, C. R. & Togni, B. Herpes simplex eye infections: clinical manifestations, pathogenesis and management. Surv. Ophthalmol.
21, 121–135 (1976).
2. Farooq, A. V. & Shukla, D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv. Ophthalmol. 57, 448–462
(2012).
3. Waggoner-Fountain, L. A. & Grossman, L. B. Herpes simplex virus. Pediatr. Rev. 25, 86–93 (2004).
4. Fields, B. N., Knipe, D. M., Howley, P. M. & Griffin, D. E. Fields virology (Lippincott Williams & Wilkins, Philadelphia, 2001).
5. Stevens, J. G. & Cook, M. L. Latent herpes simplex virus in spinal ganglia of mice. Science 173, 843–845 (1971).
6. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen Recognition and Innate Immunity. Cell 124, 783–801 (2006).
7. Chen, N. et al. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life 69, 297–304 (2017).
8. Cheng, G., Zhong, J., Chung, J. & Chisari, F. V. Double-stranded DNA and double-stranded RNA induce a common antiviral
signaling pathway in human cells. Proc. Natl. Acad. Sci. 104, 9035–9040 (2007).
9. Cheng, G., Zhong, J., Chung, J. & Chisari, F. V. Double-stranded DNA and double-stranded RNA induce a common antiviral
signaling pathway in human cells. Proc. Natl. Acad. Sci. U.S.A. 104, 9035–9040 (2007).
10. Unterholzner, L. The interferon response to intracellular DNA: Why so many receptors?. Immunobiology 218, 1312–1321 (2013).
11. Beachboard, D. C. & Horner, S. M. Innate immune evasion strategies of DNA and RNA viruses. Curr. Opin. Microbiol. 32, 113–119
(2016).
12. Conrady, C. D., Jones, H., Zheng, M. & Carr, D. J. A functional type I interferon pathway drives resistance to cornea herpes simplex
virus type 1 infection by recruitment of leukocytes. J. Biomed. Res. 25, 111–119 (2011).
13. Zheng, C. Evasion of cytosolic DNA-stimulated innate immune responses by herpes simplex virus 1. J. Virol. 92, e00099-e117
(2018).
14. Ma, W., He, H. & Wang, H. Oncolytic herpes simplex virus and immunotherapy. BMC Immunol. 19, 40–40 (2018).
15. Everett, R. D. A detailed mutational analysis of Vmw110, a trans-acting transcriptional activator encoded by herpes simplex virus
type 1. EMBO J. 6, 2069–2076 (1987).
16. Everett, R., O’Hare, P., O’Rourke, D., Barlow, P. & Orr, A. Point mutations in the herpes simplex virus type 1 Vmw110 RING finger helix affect activation of gene expression, viral growth, and interaction with PML-containing nuclear structures. J. Virol. 69,
7339–7344 (1995).
17. Lium, E. K. & Silverstein, S. Mutational analysis of the herpes simplex virus type 1 ICP0 C3HC4 zinc ring finger reveals a requirement for ICP0 in the expression of the essential alpha27 gene. J. Virol. 71, 8602–8614 (1997).
18. Everett, R. D. Construction and characterization of herpes simplex virus type 1 mutants with defined lesions in immediate early
gene 1. J. Gen. Virol. 70(Pt 5), 1185–1202 (1989).
19. Wilcox, C. L., Smith, R. L., Everett, R. D. & Mysofski, D. The herpes simplex virus type 1 immediate-early protein ICP0 is necessary
for the efficient establishment of latent infection. J. Virol. 71, 6777–6785 (1997).
20. Cai, W. et al. The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency. J. Virol. 67, 7501–7512 (1993).
21. Leib, D. A. et al. Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes
simplex virus latency. J. Virol. 63, 759–768 (1989).
22. Halford, W. P. & Schaffer, P. A. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency. J.
Virol. 75, 3240–3249 (2001).
23. Harris, R. A., Everett, R. D., Zhu, X. X., Silverstein, S. & Preston, C. M. Herpes simplex virus type 1 immediate-early protein
Vmw110 reactivates latent herpes simplex virus type 2 in an in vitro latency system. J. Virol. 63, 3513–3515 (1989).
24. Preston, C. M. & Nicholl, M. J. Repression of gene expression upon infection of cells with herpes simplex virus type 1 mutants
impaired for immediate-early protein synthesis. J. Virol. 71, 7807–7813 (1997).
25. Samaniego, L. A., Neiderhiser, L. & DeLuca, N. A. Persistence and expression of the herpes simplex virus genome in the absence
of immediate-early proteins. J. Virol. 72, 3307–3320 (1998).
26. Rezuchova, I. et al. Transcription at early stages of herpes simplex virus 1 infection and during reactivation. Intervirology 46, 25–34
(2003).
27. Maul, G. G. & Everett, R. D. The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family,
is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICP0. J. Gen. Virol. 75(Pt 6), 1223–1233 (1994).
28. Everett, R. D. & Maul, G. G. HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J. 13, 5062–5069 (1994).
29. Everett, R. D. et al. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasomedependent loss of several PML isoforms. J. Virol. 72, 6581–6591 (1998).
30. Muller, S. & Dejean, A. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 73, 5137–5143 (1999).

Scientific Reports |
Vol:.(1234567890)

(2020) 10:22216 |

https://doi.org/10.1038/s41598-020-77725-4

Content courtesy of Springer Nature, terms of use apply. Rights reserved

8

www.nature.com/scientificreports/
31. Chelbi-Alix, M. K. & de The, H. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML
and Sp100 proteins. Oncogene 18, 935–941 (1999).
32. Lukashchuk, V. & Everett, R. D. Regulation of ICP0-null mutant herpes simplex virus type 1 infection by ND10 components ATRX
and hDaxx. J. Virol. 84, 4026–4040 (2010).
33. Gu, H., Zheng, Y. & Roizman, B. Interaction of herpes simplex virus ICP0 with ND10 bodies: a sequential process of adhesion,
fusion, and retention. J. Virol. 87, 10244–10254 (2013).
34. Andres, M. E. et al. CoREST: a functional corepressor required for regulation of neural-specific gene expression. Proc. Natl. Acad.
Sci. U.S.A. 96, 9873–9878 (1999).
35. Roizman, B., Gu, H. & Mandel, G. The first 30 minutes in the life of a virus: unREST in the nucleus. Cell Cycle 4, 1019–1021 (2005).
36. Ballas, N., Grunseich, C., Lu, D. D., Speh, J. C. & Mandel, G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 121, 645–657 (2005).
37. Lunyak, V. V. et al. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 298, 1747–1752
(2002).
38. Paladino, P., Collins, S. E. & Mossman, K. L. Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to
block IRF3-mediated innate immune responses. PLoS ONE 5, e10428 (2010).
39. Wang, S., Wang, K., Lin, R. & Zheng, C. Herpes simplex virus 1 serine/threonine kinase US3 hyperphosphorylates IRF3 and inhibits
beta interferon production. J. Virol. 87, 12814–12827 (2013).
40. Zhang, J., Wang, K., Wang, S. & Zheng, C. Herpes simplex virus 1 E3 ubiquitin ligase ICP0 protein inhibits tumor necrosis factor
alpha-induced NF-κB activation by interacting with p65/RelA and p50/NF-κB1. J. Virol. 87, 12935–12948 (2013).
41. Su, C., Zhan, G. & Zheng, C. Evasion of host antiviral innate immunity by HSV-1, an update. Virol. J. 13, 38–38 (2016).
42. Orzalli, M. H., DeLuca, N. A. & Knipe, D. M. Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc. Natl. Acad. Sci. U.S.A. 109, E3008–E3017 (2012).
43. Everett, R. D., Young, D. F., Randall, R. E. & Orr, A. STAT-1- and IRF-3-dependent pathways are not essential for repression of
ICP0-null mutant herpes simplex virus type 1 in human fibroblasts. J. Virol. 82, 8871–8881 (2008).
44. van Lint, A. L. et al. Herpes simplex virus immediate-early ICP0 protein inhibits Toll-like receptor 2-dependent inflammatory
responses and NF-kappaB signaling. J. Virol. 84, 10802–10811 (2010).
45. Higgs, R. et al. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitinmediated degradation of IRF3. J. Immunol. 181, 1780–1786 (2008).
46. Xu, H., Su, C., Pearson, A., Mody, C. H. & Zheng, C. Herpes simplex virus 1 UL24 abrogates the DNA sensing signal pathway by
inhibiting NF-κB activation. J. Virol. 91, e00025-e117 (2017).
47. Zhang, J., Wang, S., Wang, K. & Zheng, C. Herpes simplex virus 1 DNA polymerase processivity factor UL42 inhibits TNF-αinduced NF-κB activation by interacting with p65/RelA and p50/NF-κB1. Med. Microbiol. Immunol. 202, 313–325 (2013).
48. Ye, R., Su, C., Xu, H. & Zheng, C. Herpes simplex virus 1 ubiquitin-specific protease UL36 abrogates NF-κB activation in DNA
sensing signal pathway. J. Virol. 91, e02417-e2516 (2017).
49. Xing, J. et al. Herpes simplex virus 1-encoded tegument protein VP16 abrogates the production of beta interferon (IFN) by inhibiting NF-κB activation and blocking IFN regulatory factor 3 to recruit its coactivator CBP. J. Virol. 87, 9788–9801 (2013).
50. Huang, J. et al. Herpes simplex virus 1 tegument protein VP22 abrogates cGAS/STING-mediated antiviral innate immunity. J.
Virol. 92, e00841-e918 (2018).
51. Gülpinar, M. A. & Yeğen, B. Ç. Interactive lecturing for meaningful learning in large groups. Med. Teach. 27, 590–594 (2005).
52. Szabo, A. & Rajnavolgyi, E. Collaboration of Toll-like and RIG-I-like receptors in human dendritic cells: tRIGgering antiviral
innate immune responses. Am. J. Clin. Exp. Immunol. 2, 195–207 (2013).
53. Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.
Nat. Immunol. 5, 730–737 (2004).
54. Negishi, H. et al. Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat. Immunol.
13, 659–666 (2012).
55. Kawai, T. & Akira, S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 21, 317–337 (2009).
56. Taylor, K. E., Chew, M. V., Ashkar, A. A. & Mossman, K. L. Novel roles of cytoplasmic ICP0: proteasome-independent functions
of the RING finger are required to block interferon-stimulated gene production but not to promote viral replication. J. Virol. 88,
8091–8101 (2014).
57. Xing, J., Wang, S., Lin, R., Mossman, K. L. & Zheng, C. Herpes simplex virus 1 tegument protein US11 downmodulates the RLR
signaling pathway via direct interaction with RIG-I and MDA-5. J. Virol. 86, 3528–3540 (2012).
58. Liu, X., Main, D., Ma, Y. & He, B. Herpes simplex virus 1 inhibits TANK-binding kinase 1 through formation of the Us11-Hsp90
complex. J. Virol. 92, e00402-e418 (2018).
59. Lin, R., Noyce, R. S., Collins, S. E., Everett, R. D. & Mossman, K. L. The herpes simplex virus ICP0 RING finger domain inhibits
IRF3- and IRF7-mediated activation of interferon-stimulated genes. J. Virol. 78, 1675–1684 (2004).
60. Daffis, S. et al. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West
Nile virus infection. J. Virol. 82, 8465–8475 (2008).
61. Honda, K. et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434, 772–777 (2005).
62. Murphy, A. A., Rosato, P. C., Parker, Z. M., Khalenkov, A. & Leib, D. A. Synergistic control of herpes simplex virus pathogenesis
by IRF-3, and IRF-7 revealed through non-invasive bioluminescence imaging. Virology 444, 71–79 (2013).
63. Melroe, G. T., Silva, L., Schaffer, P. A. & Knipe, D. M. Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0
nuclear foci: potential role in blocking IFN-β induction. Virology 360, 305–321 (2007).
64. Orzalli, M. H., DeLuca, N. A. & Knipe, D. M. Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc. Natl. Acad. Sci. 109, E3008–E3017 (2012).
65. Zhu, F. X., King, S. M., Smith, E. J., Levy, D. E. & Yuan, Y. A Kaposi’s sarcoma-associated herpesviral protein inhibits virus-mediated
induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc. Natl. Acad. Sci. 99, 5573–5578
(2002).
66. Hahn, A. M., Huye, L. E., Ning, S., Webster-Cyriaque, J. & Pagano, J. S. Interferon regulatory factor 7 is negatively regulated by the
Epstein–Barr virus immediate-early gene, BZLF-1. J. Virol. 79, 10040–10052 (2005).
67. Chen, C. W. Adverse side effects caused by topically applied antiviral agents in herpetic keratitis. Gaoxiong Yi Xue Ke Xue Za Zhi
5, 416–429 (1989).
68. Naito, T., Shiota, H. & Mimura, Y. Side effects in the treatment of herpetic keratitis. Curr. Eye Res. 6, 237–239 (1987).
69. Howell, J. B. Eye diseases induced by topically applied steroids. The thin edge of the wedge. Arch. Dermatol. 112, 1529–1530 (1976).
70. David, D. S. & Berkowitz, J. S. Ocular effects of topical and systemic corticosteroids. Lancet 2, 149–151 (1969).
71. James, E. R. The etiology of steroid cataract. J. Ocul. Pharmacol. Ther. 23, 403–420 (2007).
72. Robbins, R. M. & Galin, M. A. A model for steroid effects in herpes keratitis. Arch. Ophthalmol. 93, 828–830 (1975).
73. Dawson, C., Togni, B., Moore, T. E. Jr. & Coleman, V. Herpesvirus infection of human mesodermal tissue (cornea) detected by
electron microscopy. Nature 217, 460–462 (1968).
74. De Kesel, R. J., Koppen, C., Ieven, M. & Zeyen, T. Primary graft failure caused by herpes simplex virus type 1. Cornea 20, 187–190
(2001).
75. Foster, C. S. & Duncan, J. Penetrating keratoplasty for herpes simplex keratitis. Am. J. Ophthalmol. 92, 336–343 (1981).

Scientific Reports |

(2020) 10:22216 |

https://doi.org/10.1038/s41598-020-77725-4

Content courtesy of Springer Nature, terms of use apply. Rights reserved

9
Vol.:(0123456789)

www.nature.com/scientificreports/
76. Pan, D. et al. A neuron-specific host microRNA targets herpes simplex virus-1 ICP0 expression and promotes latency. Cell Host
Microbe 15, 446–456 (2014).
77. Umbach, J. L. et al. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 454,
780–783 (2008).
78. Jiang, X. et al. Increased neurovirulence and reactivation of the herpes simplex virus type 1 latency-associated transcript (LAT)negative mutant dLAT2903 with a disrupted LAT miR-H2. J. Neurovirol. 22, 38–49 (2016).
79. Tsambaos, D. et al. Long-term remission of recurrent herpes labialis following topical imiquimod application on distant healthy
skin: a clinical and immunological study. Antivir. Ther. 16, 863–869 (2011).
80. Cannon, P. S., O’Donnell, B., Huilgol, S. C. & Selva, D. The ophthalmic side-effects of imiquimod therapy in the management of
periocular skin lesions. Br. J. Ophthalmol. 95, 1682–1685 (2011).
81. Reuven, E. M., Fink, A. & Shai, Y. Regulation of innate immune responses by transmembrane interactions: lessons from the TLR
family. Biochim. Biophys. Acta 1838, 1586–1593 (2014).
82. Herbst-Kralovetz, M. & Pyles, R. Toll-like receptors, innate immunity and HSV pathogenesis. Herpes 13, 37–41 (2006).
83. Mansur, D. S. et al. Lethal encephalitis in myeloid differentiation factor 88-deficient mice infected with herpes simplex virus 1.
Am. J. Pathol. 166, 1419–1426 (2005).
84. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301, 640–643
(2003).
85. Hoebe, K. et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424, 743–748 (2003).
86. Lim, H. K. et al. TLR3 deficiency in herpes simplex encephalitis: high allelic heterogeneity and recurrence risk. Neurology 83,
1888–1897 (2014).
87. Sancho-Shimizu, V. et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J. Clin.
Investig. 121, 4889–4902 (2011).
88. Gabhann, J. N. et al. Absence of SHIP-1 results in constitutive phosphorylation of tank-binding kinase 1 and enhanced TLR3dependent IFN-beta production. J. Immunol. 184, 2314–2320 (2010).

Acknowledgements

This work was supported by the Health Research Board and the Royal Victoria Eye and Ear Hospital Research
Foundation through the Medical Research Charities Group. None of the funding bodies had any role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions

J.N.G.D., R.K., D.S., C.J. and C.M. wrote the main manuscript text. J.N.G.D., D.S., C.J. and C.W. contributed to
Figs. 1, 2, 3, 4. All authors reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-77725-4.
Correspondence and requests for materials should be addressed to J.N.-D.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2020

Scientific Reports |
Vol:.(1234567890)

(2020) 10:22216 |

https://doi.org/10.1038/s41598-020-77725-4

Content courtesy of Springer Nature, terms of use apply. Rights reserved

10

Terms and Conditions
Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).
Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for smallscale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By
accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these
purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.
These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal
subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription
(to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will
apply.
We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within
ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not
otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as
detailed in the Privacy Policy.
While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may
not:
1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access
control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is
otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval , sponsorship, or association unless explicitly agreed to by Springer Nature in
writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal
content.
In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue,
royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal
content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any
other, institutional repository.
These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or
content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature
may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.
To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied
with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law,
including merchantability or fitness for any particular purpose.
Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed
from third parties.
If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not
expressly permitted by these Terms, please contact Springer Nature at
onlineservice@springernature.com

